NCT01553916

Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain

Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase I/II trial studies the effects and safety of giving lithium carbonate (lithium) to patients with small cell lung cancer (SCLC) undergoing radiation therapy to the brain (PCI; prophylactic cranial irradiation). PCI is used to prevent cancer metastases from returning in the brain. This treatment can cause short-term memory problems by damaging the hippocampus. Lithium may help prevent or lessen memory problems caused by PCI by protecting the hippocampus.

Conditions

• Small Cell Lung Carcinoma

Interventions

Type	Name	Description
DRUG	Lithium Carbonate
RADIATION	Prophylactic cranial irradiation

Timeline

• Start date: 2012-04-26
• Primary completion: 2016-09-12
• Completion: 2017-06-05
• First posted: 2012-03-14
• Last updated: 2018-07-05
• Results posted: 2017-11-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study